The Institute for Clinical and Economic Review (ICER) has posted the draft report, “The Comparative Clinical Effectiveness and Value of Novel Combination Therapies for the Treatment of Patients with Genotype 1 Chronic Hepatitis C Infection” for public comment.
Providing credible, evidence-based information about medical technologies, treatments, and models of care
CTAF has long been recognized as one of the leading technology assessment programs in the country. In 2013, CTAF became a core program of the Institute for Clinical and Economic Review, and its approach has now been adapted to broaden stakeholder engagement and improve the application of CTAF products in practice and policy. Learn more »
Attend a Meeting
April 2, 2015
ICER’s report for CTAF will assess the evidence on the comparative clinical effectiveness and value of efforts to integrate behavioral health into primary care; identify the components potentially associated with successful integration; and evaluate the legal, regulatory, and financial landscape for behavioral health integration (BHI) in California. The report will also include an overview of lessons learned from national and California-based experts to identify potential innovations and solutions for BHI in the state.
Sign up to receive email notifications of upcoming CTAF meetings and new assessments. All fields required.